Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the ...

Eli Lilly's portfolio, both within and outside its core area, makes the stock attractive. However, a recent move Eli Lilly made reveals an underrated reason why the stock has attractive prospects.

The Schwab U.S. Dividend Equity ETF has a higher yield and has sharply increased its dividend. However, the Vanguard Dividend ...

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and ...

During Q1 2025, the Harbor Capital Appreciation Fund returned -10.07%, underperforming its benchmark, the Russell 1000® ...